Abstracts Archive - Page 2297 of 2425 - ACR Meeting Abstracts

Abstract Number: 1898 • 2012 ACR/ARHP Annual Meeting
A Competence-Based Model for Teaching Rheumatology in Undergraduate Medical Students in Pontificia Universidad Católica De Chile: A Five Years Experience
Pamela Díaz, Carolina Cuellar, Miguel Gutiérrez and Marcela Cisternas, Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: Several reports have demonstrated that Rheumatology disorders are increasingly arising. In USA, for example, three of the top eight primary diagnosis groups presenting to…
Abstract Number: 1859 • 2012 ACR/ARHP Annual Meeting
The Polysymptomatic Distress Scale and the Effect of Age On Polysymptomatic Distress and Fibromyalgia: A Survey in a Representative Population Sample
Winfried Häuser¹, Frederick Wolfe², Johannes Rasker³, Elmar Brähler⁴ and Heide Glaesmer⁴, ¹Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Dpt. Psychology, Health and Technology, University Twente, Enschede, Netherlands, ⁴University of Leipzig, Leipzig, Germany
Background/Purpose : Recent advances in the definition of the fibromyalgia syndrome (FM) have led to the development of the polysymptomatic distress (PSD) scale, providing a…
Abstract Number: 1860 • 2012 ACR/ARHP Annual Meeting
Fibromyalgia and the Disease and Statistical Manual Classification As a Somatic Symptom Disorder
Frederick Wolfe¹, Brian T. Walitt² and Winfried Häuser³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Rheumatology, Washington Hospital Center, Washington, DC, ³Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany
Background/Purpose: Fibromyalgia was first defined by rheumatologists, and is often thought of as a disorder of widespread pain and decreased pain threshold. In the wider…
Abstract Number: 1861 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin in Japanese Patients with Fibromyalgia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase III Trial and Open-Label Extension Study
Hiroyoshi Ohta¹, Masayuki Ohkura¹, Makoto Suzuki¹, Hiroshi Oka², Chie Usui³ and Kusuki Nishioka⁴, ¹Pfizer Japan Inc, Tokyo, Japan, ²Rheumatic Disease Center, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, ³Department of Psychiatry, Juntendo University School of Medicine, Juntendo University Nerima Hospital, Tokyo, Japan, ⁴Institute of Innovative Medical Science and Education, Tokyo Medical University, Tokyo, Japan
Background/Purpose: Fibromyalgia (FM) is a common, chronic pain disorder, however, at the time of this study there was no approved medicine for FM patients in…
Abstract Number: 1862 • 2012 ACR/ARHP Annual Meeting
The 2012 Canadian Fibromyalgia Guidelines: Clinically Applicable Recommendations for the Management of Fibromyalgia
Mary-Ann Fitzcharles¹, Peter A. Ste-Marie², Don L. Goldenberg³, John X. Pereira⁴, Susan Abbey⁵, Manon Choinière², Gordon Ko⁵, Dwight Moulin⁶, Pantelis Panopalis⁷, Johanne Proulx⁸ and Yoram Shir⁹, ¹Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²University of Montreal, Montreal, QC, Canada, ³Rheumatology, Newton-Wellesley Hosp, Newton, MA, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Western Ontario, London, ON, Canada, ⁷Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁸Patient Representative, Montreal, QC, Canada, ⁹Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The healthcare community remains challenged regarding the care of fibromyalgia (FM) patients. Previous guidelines have mostly addressed treatment options rather than provide an overall…
Abstract Number: 1863 • 2012 ACR/ARHP Annual Meeting
Resetting the Naming Speed Clock with Methylphenidate (Ritalin)
Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL
Background/Purpose: Abnormalities in naming speed are an unappreciated feature of cognitive dysfunction in fibromyalgia (FMS). Approximately 50% of FMS patients with memory problems name words…
Abstract Number: 1864 • 2012 ACR/ARHP Annual Meeting
Swimming Is As Effective As Walking for Treating Fibromyalgia: A Randomized Controlled Trial
Giovana Fernandes, Fabio Jennings, Michele V. Nery, Ana Leticia P. de Buosi and Jamil Natour, Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Fibromyalgia (FM) is a chronic widespread pain syndrome that causes deterioration of physical capacity. Exercises are fundamental in the treatment of FM and walking…
Abstract Number: 1865 • 2012 ACR/ARHP Annual Meeting
Emotional Pain and Catastrophizing Influence Quality of Life in Fibromyalgia
Neda Faregh¹, Peter A. Ste-Marie² and Mary-Ann Fitzcharles³, ¹McGill University, Montreal, QC, Canada, ²Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Fibromyalgia (FM) is a composite of symptoms with the pivot symptom of pain, traditionally measured as intensity with little attention to other qualities. Emotional…
Abstract Number: 1866 • 2012 ACR/ARHP Annual Meeting
Association of Opioid Use with Symptom Severity and Quality of Life in Patients with Fibromyalgia
Terry H. Oh¹, Chul H. Kim², Connie A. Luedtke³, Jeffrey Thompson¹, W. Michael Hooten⁴ and Ann Vincent⁵, ¹Pm&r, Mayo Clinic, Rochester, MN, ²Kyungpook National University, Daegu, South Korea, ³Nursing, Mayo Clinic, Rochester, MN, ⁴Anesthesiology, Mayo Clinic, Rochester, MN, ⁵General Internal Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Chronic widespread pain is a cardinal symptom in patients with fibromyalgia. Current pharmacotherapies for fibromyalgia targets central neurochemical abnormalities and pain processing pathways. Analgesics…
Abstract Number: 1867 • 2012 ACR/ARHP Annual Meeting
Assessment of ART Therapy Program for Women with Fibromyalgia: Randomized, Controlled, Blinded Study
Andreia S. Baptista¹, Anamaria Jones¹, Fernanda P. Cardoso¹, Betina C. Schaffir¹, Elisa R. W. Coelho¹, Aline Orlandi¹ and Jamil Natour², ¹Unifesp-EPM, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Fibromyalgia (FM) is a chronic non-inflammatory syndrome characterized by diffuse pain throughout the body, sleep disorder, stiffness, fatigue, depression and other psychological problems. Patients…
Abstract Number: 1868 • 2012 ACR/ARHP Annual Meeting
Clinical Outcome in Fibromyalgia Patients Treated with Milnacipran Is Largely Independent of Symptom Duration
Philip J. Mease¹, Robert M. Bennett², Robert H. Palmer³ and Yong Wang⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine & Nursing, Oregon Health & Science University, Portland, OR, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: Patients with fibromyalgia (FM) usually experience pain, fatigue, and other debilitating symptoms for years. In clinical studies ranging from 3 months to >3 years,…
Abstract Number: 1869 • 2012 ACR/ARHP Annual Meeting
Predictors of Fatigue in Fibromyalgia
Ann Vincent¹, Mary O. Whipple², Debra L. Barton³, Daniel J. Clauw⁴, David A. Williams⁵, Terry H. Oh⁶ and Loren L. Toussaint⁷, ¹General Internal Medicine, Mayo Clinic, Rochester, MN, ²Fibromyalgia and Chronic Fatigue Clinic, Mayo Clinic, Rochester, MN, ³Oncology, Mayo Clinic, Rochester, MN, ⁴Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁵Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI, ⁶Physical Medicine & Rehabilitation, Mayo Clinic, Rochester, MN, ⁷Psychology, Luther College, Decorah, IA
Background/Purpose: Previous research suggests that fatigue in chronic diseases is multifactorial and that fatigue in fibromyalgia is worse than fatigue in rheumatoid arthritis or osteoarthritis.…
Abstract Number: 1870 • 2012 ACR/ARHP Annual Meeting
Financial Conflicts of Interest and Industry Sponsorship Are Associated with Positive Outcomes in Fibromyalgia Randomized Controlled Trials
Winnie K. Pang¹, Karen Yeter², Nasim A. Khan³ and Karina D. Torralba¹, ¹Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Fibromyalgia randomized controlled trials (RCTs) have become more common in the past 15 years, in part due to industry sponsorship. Recently, there has been…
Abstract Number: 1871 • 2012 ACR/ARHP Annual Meeting
Tender Point Count and Pressure Pain Threshold As Predictors of Chronic Widespread Pain and Health Status in a Seven Year Prospective Study
Emma Jacobsen¹ and Stefan Bergman², ¹R&D center Spenshult, Oskarström, Sweden, ²Spenshult Research and Development Center, Halmstad, Sweden
Background/Purpose: Chronic widespread pain is common in the general population with a prevalence ranging between 4.2% and 13.3%. It has been identified as a major…
Abstract Number: 1872 • 2012 ACR/ARHP Annual Meeting
Quality of Reporting in Pharmacological Randomized Controlled Trials for Fibromyalgia
Karen Yeter¹, Winnie Pang², Nasim A. Khan³ and Karina D. Torralba², ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Randomized controlled trials (RCTs) are considered the gold standard for assessment of healthcare interventions. Recently, there have been growing concerns about the quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].